The effect of antiresorptives on bone quality.
Background: Currently, antiresorptive therapy in the treatment and prevention of osteoporosis includes bisphosphonates, estrogen replacement, selective estrogen receptor modulators (raloxifene), and denosumab (a human antibody that inactivates RANKL). The original paradigm driving the development of...
| Published in: | Clinical Orthopaedics & Related Research® Vol. 469; no. 8; pp. 2207 - 2215 |
|---|---|
| Main Authors: | , , , |
| Format: | research review Journal Article |
| Published: |
Lippincott Williams & Wilkins
Aug2011
|
| Online Access: | View this record in EBSCOhost |